Morgan Stanley
RNAC icon

Morgan Stanley’s Cartesian Therapeutics RNAC Stock Holding History

Morgan Stanley’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91.1K Sell
14,805
-8,489
-36% -$60.5K ﹤0.01% 6206
2025
Q4 		$168K Buy
23,294
+4,320
+23% +$34.9K ﹤0.01% 5996
2025
Q3 		$194K Sell
18,974
-10,239
-35% -$115K ﹤0.01% 5905
2025
Q2 		$304K Buy
29,213
+11,363
+64% +$121K ﹤0.01% 5683
2025
Q1 		$235K Sell
17,850
-6,412
-26% -$115K ﹤0.01% 5664
2024
Q4 		$435K Buy
24,262
+2,251
+10% +$45.6K ﹤0.01% 5480
2024
Q3 		$355K Buy
22,011
+14,764
+204% +$231K ﹤0.01% 5550
2024
Q2 		$196K Sell
7,247
-118
-2% -$2.82K ﹤0.01% 5687
2024
Q1 		$144K Sell
7,365
-11,627
-61% -$247K ﹤0.01% 5855
2023
Q4 		$393K Buy
18,992
+13,244
+230% +$395K ﹤0.01% 5711
2023
Q3 		$183K Sell
5,748
-2,700
-32% -$90.2K ﹤0.01% 5624
2023
Q2 		$284K Sell
8,448
-498
-6% -$17.8K ﹤0.01% 5485
2023
Q1 		$373K Buy
8,946
+4,166
+87% +$196K ﹤0.01% 5422
2022
Q4 		$162K Buy
4,780
+1,732
+57% +$73.7K ﹤0.01% 5754
2022
Q3 		$150K Sell
3,048
-27,922
-90% -$1.53M ﹤0.01% 5876
2022
Q2 		$1.22M Buy
30,970
+3,428
+12% +$102K ﹤0.01% 4896
2022
Q1 		$1.02M Sell
27,542
-15,437
-36% -$966K ﹤0.01% 4985
2021
Q4 		$4.2M Buy
42,979
+26,812
+166% +$2.88M ﹤0.01% 3891
2021
Q3 		$2.02M Buy
16,167
+5
+0% +$604 ﹤0.01% 4573
2021
Q2 		$2.03M Sell
16,162
-11,240
-41% -$1.34M ﹤0.01% 4621
2021
Q1 		$3.72M Sell
27,402
-16,566
-38% -$2.06M ﹤0.01% 3719
2020
Q4 		$4M Buy
43,968
+43,529
+9,915% +$3.77M ﹤0.01% 3498
2020
Q3 		$32K Sell
439
-4,714
-91% -$361K ﹤0.01% 5880
2020
Q2 		$439K Buy
5,153
+4,432
+615% +$402K ﹤0.01% 4666
2020
Q1 		$52K Buy
721
+114
+19% +$11K ﹤0.01% 5454
2019
Q4 		$43K Buy
607
+93
+18% +$4.49K ﹤0.01% 5900
2019
Q3 		$27K Sell
514
-1,612
-76% -$85.7K ﹤0.01% 5929
2019
Q2 		$114K Buy
2,126
+1,814
+581% +$124K ﹤0.01% 5263
2019
Q1 		$22K Sell
312
-702
-69% -$44.5K ﹤0.01% 5978
2018
Q4 		$81K Sell
1,014
-170
-14% -$38.8K ﹤0.01% 5624
2018
Q3 		$552K Sell
1,184
-117
-9% -$47K ﹤0.01% 4946
2018
Q2 		$517K Buy
1,301
+274
+27% +$97.2K ﹤0.01% 5077
2018
Q1 		$314K Buy
1,027
+2
+0.2% +$570 ﹤0.01% 5262
2017
Q4 		$302K Buy
1,025
+335
+49% +$146K ﹤0.01% 5251
2017
Q3 		$378K Buy
690
+158
+30% +$84K ﹤0.01% 5038
2017
Q2 		$317K Buy
532
+218
+69% +$96.3K ﹤0.01% 5077
2017
Q1 		$135K Sell
314
-184
-37% -$77.4K ﹤0.01% 5494
2016
Q4 		$256K Buy
498
+446
+858% +$261K ﹤0.01% 5253
2016
Q3 		$22K Buy
+52
New +$20.3K ﹤0.01% 5887

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley's RNAC Position: Q1 2026 in Review

Morgan Stanley reduced its Cartesian Therapeutics (RNAC) stake by 36% in Q1 2026, selling an estimated $60.5K and leaving 14,805 shares worth $91.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6206.

Morgan Stanley first reported a position in RNAC in Q3 2016 and has held it in 39 quarters since. The position peaked at $4.2M in Q4 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Morgan Stanley held 14,805 shares of Cartesian Therapeutics worth $91.1K as of Q1 2026.
  • Morgan Stanley sold 8,489 Cartesian Therapeutics shares in Q1 2026, an estimated $60.5K.
  • Cartesian Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6206 holding.
  • Morgan Stanley first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • Morgan Stanley's Cartesian Therapeutics position peaked at $4.2M in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.